Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists-Reference-Cited by-同舟云学术

Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists

Published:2022-11 Issue:6 Volume:48 Page:101390
ISSN:1262-3636
Container-title:Diabetes & Metabolism
language:en
Short-container-title:Diabetes & Metabolism

Author:

Scheen André J.^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference122 articles.

1. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies;Bell;Diabetes Obes Metab,2019

2. Atrial fibrillation and diabetes mellitus: JACC review topic of the week;Wang;J Am Coll Cardiol,2019

3. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease;Movahed;Int J Cardiol,2005

4. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies;Aune;J Diabetes Complicat,2018

5. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study;Seyed Ahmadi;Cardiovasc Diabetol,2020

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis;European Journal of Medical Research;2024-07-31

2. Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis;PLOS ONE;2024-06-24

3. Analysis of the contribution of obstructive sleep apnea/hypopnea syndrome and glycemic level variability to the development and progression of cardiac arrhythmias in patients with type 2 diabetes mellitus;Diabetes mellitus;2024-05-06

4. Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference;Europace;2024-03-30

5. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation;The Journal of Clinical Endocrinology & Metabolism;2024-03-11